Curie.bio

Curie.Bio is a unique combination of two businesses: they act as both your drug discovery copilot & seed investor. They have some of the world’s best drug hunters, drug makers, experts, and vendors supporting their founders to increase their chances of developing successful medicines.

Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing.

Curie.Bio has raised a total of $520M in a single venture fund, Curie Bio Seed Fund I. This fund was announced on Feb 14, 2023 and raised a total of $520M.

The new VC is composed of two different entities: an investing vehicle that will provide seed-stage money to startups and a unit that will provide various services to help companies move their science forward. In total, the venture has raised $520 million from an assortment of investors, including GV, ARCH Venture Partners and a16z.

Applicants willing to get in touch with Curie.bio can submit their forms by following this link.

Portfolio: Tango Therapeutics, Relay Therapeutics, Revolution Medicines, Blueprint Medicines.